Valuation dashboard for Inventiva S.A. (IVA) with P/E N/A, P/B -71.60, EV/EBITDA -5.72 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases.
Analysis Summary
Inventiva S.A. reported revenue of $4.5M in the most recent fiscal year, growing at a 5-year CAGR of 64.5%.
Trailing-twelve-month margins: gross margin 35.1%, operating margin -30.4%, net margin -79.0%.
At the current price of $3.79, IVA has negative trailing earnings (P/E not meaningful) and an ROE of 18.70%. Market capitalisation stands at $197M.
Balance sheet quality for IVA: current ratio of 3.2. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -71.60 |
| EV / EBITDA | -5.72 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| IVA | Inventiva S.A. | $197M | 18.7% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $3.79 |
| Market Cap | $197M |
| Exchange | NASDAQ |
| Country | FR |
Profitability
| Return on Equity | 1870.38% |
| Return on Invested Capital | -66.18% |
| Return on Assets | -141.93% |
| Gross Margin | 35.07% |
| Operating Margin | -3037.30% |
| Net Margin | -7899.58% |
Related companies: AVTX · CRBU · ENTA · EPRX · GNFT · IVVD · NAUT
Explore sector: Healthcare · Biotechnology
More sections of IVA: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks